| Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer MA Rice, SV Malhotra, T Stoyanova Frontiers in oncology 9, 801, 2019 | 340 | 2019 |
| Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer A Ghoochani, EC Hsu, M Aslan, MA Rice, HM Nguyen, JD Brooks, ... Cancer research 81 (6), 1583-1594, 2021 | 225 | 2021 |
| Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 EC Hsu, MA Rice, A Bermudez, FJG Marques, M Aslan, S Liu, ... Proceedings of the National Academy of Sciences 117 (4), 2032-2042, 2020 | 126 | 2020 |
| Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer T Stoyanova, M Riedinger, S Lin, CM Faltermeier, BA Smith, KX Zhang, ... Proceedings of the National Academy of Sciences 113 (42), E6457-E6466, 2016 | 62 | 2016 |
| Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies MA Rice, EC Hsu, M Aslan, A Ghoochani, A Su, T Stoyanova Molecular Cancer Therapeutics, 2019 | 56 | 2019 |
| Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. N Zhao, P Stephanie O, C Hao Lo, H Laine M, MA Rice, CD Fahrenholtz, ... Sci Trans Med 11, 2019 | 54 | 2019 |
| Plectin is a regulator of prostate cancer growth and metastasis M Buckup, MA Rice, EC Hsu, F Garcia-Marques, S Liu, M Aslan, ... Oncogene 40 (3), 663-676, 2021 | 48 | 2021 |
| The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related MA Rice, RA Ishteiwy, F Magani, T Udayakumar, T Reiner, TJ Yates, ... Oncogene 1, 10, 2016 | 47 | 2016 |
| Oncogene-mediated metabolic gene signature predicts breast cancer outcome M Aslan, EC Hsu, FJ Garcia-Marques, A Bermudez, S Liu, M Shen, ... NPJ Breast Cancer 7 (1), 141, 2021 | 42 | 2021 |
| NACK is an integral component of the Notch transcriptional activation complex and is critical for development and tumorigenesis KL Weaver, MC Alves-Guerra, K Jin, Z Wang, X Han, P Ranganathan, ... Cancer research 74 (17), 4741-4751, 2014 | 42 | 2014 |
| Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor ES Koltun, MA Rice, WC Gustafson, D Wilds, J Jiang, BJ Lee, Z Wang, ... Cancer research 82 (12_Supplement), 3597-3597, 2022 | 33 | 2022 |
| First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRAS … E Koltun, J Cregg, MA Rice, DM Whalen, R Freilich, J Jiang, R Hansen, ... Cancer Research 81 (13_Supplement), 1260-1260, 2021 | 32 | 2021 |
| SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer MA Rice, V Kumar, D Tailor, FJ Garcia-Marques, EC Hsu, S Liu, ... Cell Reports Medicine 3 (2), 2022 | 29 | 2022 |
| Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer S Liu, M Shen, EC Hsu, CA Zhang, F Garcia-Marques, R Nolley, K Koul, ... British journal of cancer 124 (5), 896-900, 2021 | 29 | 2021 |
| Targeting AR variant–coactivator interactions to exploit prostate cancer vulnerabilities F Magani, SO Peacock, MA Rice, MJ Martinez, AM Greene, PS Magani, ... Molecular Cancer Research 15 (11), 1469-1480, 2017 | 26 | 2017 |
| Quantitative proteomic profiling reveals key pathways in the anticancer action of methoxychalcone derivatives in triple negative breast cancer CC Going, D Tailor, V Kumar, AM Birk, M Pandrala, MA Rice, T Stoyanova, ... Journal of proteome research 17 (10), 3574-3585, 2018 | 25 | 2018 |
| Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor. WC Gustafson, D Wildes, MA Rice, BJ Lee, J Jiang, Z Wang, S Chang, ... Journal of Clinical Oncology 40 (4_suppl), 591-591, 2022 | 24 | 2022 |
| Biomarkers for diagnosis and prognosis of prostate cancer MA Rice, T Stoyanova Prostatectomy, 9, 2019 | 17 | 2019 |
| In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification J Xie, MA Rice, Z Chen, Y Cheng, EC Hsu, M Chen, G Song, L Cui, ... Cancer research 81 (9), 2510-2521, 2021 | 12 | 2021 |
| Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019; 9: 801 MA Rice, SV Malhotra, T Stoyanova | 8 | 2019 |
En-Chi HsuNational Health Research Institutes in TaiwanAdresse e-mail validée de nhri.edu.tw
